By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OXiGENE, Inc. 

230 Third Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-547-5900 Fax: 781-547-6800



Company News
OXiGENE (OXGN) Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials 9/30/2015 7:09:09 AM
OXiGENE (OXGN) Reports Second Quarter 2015 Financial Results 8/5/2015 7:43:48 AM
OXiGENE (OXGN) To Host Second Quarter Financial Results Conference Call And Webcast 7/28/2015 8:27:10 AM
OXiGENE (OXGN) Appoints Matthew M. Loar As Chief Financial Officer 7/21/2015 7:24:06 AM
OXiGENE (OXGN) Receives Guidance From FDA Supporting Phase III Trial Of Fosbretabulin/Bevacizumab Combination In Platinum-Resistant Ovarian Cancer 6/1/2015 8:10:27 AM
OXiGENE (OXGN) Announces Issuance Of U.S. Patent For OXi4503 In Acute Myeloid Leukemia 5/27/2015 6:56:50 AM
OXiGENE (OXGN) Appoints Bill Schwieterman, M.D., As President And CEO 5/13/2015 7:33:41 AM
OXiGENE (OXGN) Reports First Quarter 2015 Financial Results 5/1/2015 8:32:03 AM
OXiGENE (OXGN) Announces Participation In Upcoming Investor And Medical Conferences 4/3/2015 7:16:10 AM
OXiGENE (OXGN) Announces $10 Million At-the-Market Registered Direct Offering 3/20/2015 7:22:54 AM